African Journal of Cardiology and Cardiovascular Medicine
Editor-in-Chief: Dr. Mohd. Shahbaaz Khan | ISSN: 3136-9294 | Frequency: Biannual | Publication Format: Open Access | Language: English | Indexing/Listing :

Past Issues of African Journal of Biological Sciences

Volume 1, Issue 1, July 2025
Research Paper

Circulating inflammatory cytokine signatures and residual risk after highintensity statin therapy in acute coronary syndromes

| Open Access

Nadia E. Farouk1*
Afj.Card.Cardvm. 1(1) (2025) 20-28,https://doi.org/10.62587/AFJCCM.1.1.2025.20-28
Received: 16/03/2025|Accepted: 03/07/2025|Published: 25/07/2025

Abstract

Aim: The present study aimed to assess the possible role of circulating cytokine profile in discriminating patients for the presence of other cardiovascular risk factors in addition to conventional risk factors and LDL-C goals. Methods: Nine circulating inflammatory cytokines were measured in 560 patients with ACS who were treated with high-dose statins. Inflammatory signatures were obtained by cluster analysis without supervision. Patients were followed up for Major Adverse Cardiovascular Events (MACEs). Multivariable Cox regression with the addition of clinical risk factors and achieved LDL-C was used to assess associations with residual risk, and incremental discrimination was assessed using the C-statistic. Results: Three inflammatory signatures were identified: low-inflammatory (43%), IL-6/CRP-predominant (35%) and broad high-inflammatory (21%). No differences were seen in the results for LDL-C achieved. With a median follow-up period of 30 months, 13%, 19% and 34% of patients, respectively, experienced residual events. The high-inflammatory signature was an independent predictor of residual events (adjusted HR 2.89, 95% CI 1.81-4.59). Higher event risk occurred with each standard deviation (SD) increase in the composite inflammatory score (HR, 1.51; 95% CI, 1.27-1.79). Conclusion: A multidimensional inflammatory cytokine signature parsimoniously identified residual cardiovascular risk in addition to LDL-C and clinical risk factors in ACS patients on high-intensity statin treatment.


Keywords: Residual inflammatory risk, Interleukin-6, C-reactive protein, Acute coronary syndrome

 Full text  Download  XML